Inventor · disambiguated record
Frank Jaschinski
Also filed as: JASCHINSKI FRANK
14 granted patents·13 pending applications·168 citations·filing 2007–2024
88Inventor score
Files withSECARNA PHARMACEUTICALS GMBH & CO KG13ISARNA THERAPEUTICS GMBH7LIPIGON PHARMACEUTICALS AB3GARCIA GABRIEL1MITSCH ANDREAS1
Top patents by PatentIndex Score
27 records- 0189US8936910B2Method for selective oligonucleotide modificationMITSCH ANDREAS·Filed 2011·Granted Jan 20, 2015·69 cites·11 claims
- 0289US8088772B2Sulfonamides and their use as a medicamentGARCIA GABRIEL·Filed 2007·Granted Jan 3, 2012·87 cites·24 claims
- 0381US8476246B2Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta systemSCHLINGENSIEPEN KARL-HERMANN·Filed 2010·Granted Jul 2, 2013·11 cites·8 claims
- 0471US2024384272A1Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2024·Application pending·0 cites
- 0569US9688988B2Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2014·Granted Jun 27, 2017·1 cites·11 claims
- 0666US11781139B2ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2022·Granted Oct 10, 2023·0 cites·13 claims
- 0761US12024708B2ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2019·Granted Jul 2, 2024·0 cites·18 claims
- 0859US2025059547A1NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory diseaseSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2022·Application pending·0 cites
- 0955US9926563B2Modified TGF-beta oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2014·Granted Mar 27, 2018·0 cites·10 claims
- 1054US9840707B2Modified TGF-beta2 oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2014·Granted Dec 12, 2017·0 cites·6 claims
- 1154US2019144865A1Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2018·Application pending·0 cites
- 1252US10125368B2Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2017·Granted Nov 13, 2018·0 cites·9 claims
- 1351US2024076673A1Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 1449US10538768B2Modified TGF-beta oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2018·Granted Jan 21, 2020·0 cites·5 claims
- 1548US11781136B2Oligonucleotide inhibiting the expression of ChopSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Granted Oct 10, 2023·0 cites·12 claims
- 1648US2023183708A1PD-1-specific antisense oligonucleotide and its use in therapySECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 1747US2022372482A1Modified antisense oligonucleotide for inhibition of FoxP3 expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1846US2022372479A1Oligonucleotide based ex vivo cell therapySECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1946US2024067973A1Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infectionTHE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV·Filed 2021·Application pending·0 cites
- 2046US2018087055A1Modified tgf-beta2 oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2017·Application pending·0 cites
- 2142US11666595B2Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancerSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted Jun 6, 2023·0 cites·5 claims
- 2241US2023067620A1Inhibitor of metadherin expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 2339US2022220485A1PD-L1 antisense oligonucleotides for use in tumor treatmentSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 2437US10647987B2Approach for treating inflammatory disordersSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted May 12, 2020·0 cites·12 claims
- 2536US11959083B2Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39SECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted Apr 16, 2024·0 cites·8 claims
- 2635US2019330640A1Oligonucleotides inhibiting the expression of nrp1SECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Application pending·0 cites
- 2734US2020163988A1Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of IDOSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank Jaschinski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →